Using test positivity and reported case rates to estimate state-level COVID-19 prevalence and seroprevalence in the United States
Open Access
- 7 September 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 17 (9) , e1009374
Abstract
Accurate estimates of infection prevalence and seroprevalence are essential for evaluating and informing public health responses and vaccination coverage needed to address the ongoing spread of COVID-19 in each United States (U.S.) state. However, reliable, timely data based on representative population sampling are unavailable, and reported case and test positivity rates are highly biased. A simple data-driven Bayesian semi-empirical modeling framework was developed and used to evaluate state-level prevalence and seroprevalence of COVID-19 using daily reported cases and test positivity ratios. The model was calibrated to and validated using published state-wide seroprevalence data, and further compared against two independent data-driven mathematical models. The prevalence of undiagnosed COVID-19 infections is found to be well-approximated by a geometrically weighted average of the positivity rate and the reported case rate. Our model accurately fits state-level seroprevalence data from across the U.S. Prevalence estimates of our semi-empirical model compare favorably to those from two data-driven epidemiological models. As of December 31, 2020, we estimate nation-wide a prevalence of 1.4% [Credible Interval (CrI): 1.0%-1.9%] and a seroprevalence of 13.2% [CrI: 12.3%-14.2%], with state-level prevalence ranging from 0.2% [CrI: 0.1%-0.3%] in Hawaii to 2.8% [CrI: 1.8%-4.1%] in Tennessee, and seroprevalence from 1.5% [CrI: 1.2%-2.0%] in Vermont to 23% [CrI: 20%-28%] in New York. Cumulatively, reported cases correspond to only one third of actual infections. The use of this simple and easy-to-communicate approach to estimating COVID-19 prevalence and seroprevalence will improve the ability to make public health decisions that effectively respond to the ongoing COVID-19 pandemic.Keywords
All Related Versions
Funding Information
- National Science Foundation (NSF DEB RAPID 2028632)
- National Institute of Environmental Health Sciences (P30 ES029067)
This publication has 17 references indexed in Scilit:
- Urban Air Pollution May Enhance COVID-19 Case-Fatality and Mortality Rates in the United StatesThe Innovation, 2020
- Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional studyThe Lancet, 2020
- Association of Public Interest in Preventive Measures and Increased COVID-19 Cases After the Expiration of Stay-at-Home Orders: A Cross-Sectional StudyDisaster Medicine and Public Health Preparedness, 2020
- Substantial underestimation of SARS-CoV-2 infection in the United StatesNature Communications, 2020
- Cumulative incidence and diagnosis of SARS-CoV-2 infection in New YorkAnnals of Epidemiology, 2020
- Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020MMWR. Morbidity and Mortality Weekly Report, 2020
- Evaluating Data Types2020
- Estimating the effects of non-pharmaceutical interventions on COVID-19 in EuropeNature, 2020
- U1 snRNP regulates cancer cell migration and invasion in vitroNature Communications, 2020
- Inference from Iterative Simulation Using Multiple SequencesStatistical Science, 1992